Risultati per: I numeri del cancro in Italia 2019

Nel 2020 gli antibiotici hanno rappresentato l’1,2% dei consumi e il 3% della spesa del Servizio Sanitario Nazionale: 692 milioni. Il consumo complessivo è in riduzione (-18,2%) ma superiore alla media europea.

Stroke, Volume 53, Issue Suppl_1, Page ATMP18-ATMP18, February 1, 2022. Background:We evaluated the frequency and outcomes of Coronavirus Disease 2019 (COVID-19) associated stroke (ischemic and hemorrhagic) and myocardial infarction (MI) in a global research network.Methods:All adult (≥ 18 years) patients with ICD-10 diagnoses of COVID-19 were included and those with a stroke (ischemic stroke, intracerebral hemorrhage [ICH], transient ischemic attach [TIA] or subarachnoid hemorrhage [SAH]) or myocardial infarction (MI) ± 28 days from COVID-19 diagnosis were flagged. Individuals with a prior history of stroke / MI were excluded. COVID-19 associated stroke (CAS) and MI (CAM) frequencies were compared to prior AHA-reported population-based incidences. Severe COVID-19 disease (use of ventilator, intubation, or life support) and 90-day mortality were evaluated among no-stroke/MI and stroke/MI subgroups utilizing general linear models adjusted for age, sex, race/ethnicity, and Charlson Comorbidity Index scores. Adjusted odds ratios (aOR) and 95% confidence intervals (CI) are reported.Results:Between Jan 2020 and Jul 2021, we identified 637,820 COVID-19 patients of whom 4,559 (0.71%) had a CAS and 6,972 (1.09%) had a CAM. COVID-19 was associated with significantly higher stroke/MI rates compared to population based reported incidence (ORs, CI for CAS 1.99, 1.93 – 2.05 and CAM 3.09, 3.01 – 3.16). Severe COVID disease was observed among 1.07% of COVID-19 only patients, 11.25% of CAS patients (aOR, CI: 4.82, 4.35 – 5.34), and 14.81% of CAM patients (aOR, CI: 5.77, 5.34 – 5.22). 90-Day mortality was 1.92% for COVID-19 only patients, 14.35% for CAS patients (aOR, CI: 3.16, 2.87 – 3.46), and 20.52% for CAM patients (aOR, CI: 4.12, 3.85 – 4.41). Group specific demographic and outcome proportions are reported (Figure).Conclusion:The COVID-19 pandemic has tremendously exacerbated the burden of cerebrovascular and cardiovascular disease globally. Continued work is needed to understand drivers of poor outcomes among COVID-19 patients.

Stroke, Volume 53, Issue Suppl_1, Page A103-A103, February 1, 2022. Introduction:We sought to present burden estimates of ischemic and hemorrhagic stroke in the US in 2019 and to describe trends from 1990 to 2019 by age, sex, and geographic location.Methods:We performed an analysis of the Global Burden of Disease (GBD) 2019 study. Data on stroke incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) from 1990 to 2019 were obtained from the GBD results tool. We measured crude and age-standardized incidence, prevalence, mortality, and DALYs per 100,000 (with 95% uncertainty intervals) for all stroke, ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage from 1990 to 2019.Results:In the US in 2019, there were 0.46 million (0.40-0.52) incident strokes, of which 67.5% were ischemic (0.31 million [0.26-0.38]), 0.19 million (0.17-0.21) stroke-related deaths and 3.83 million (3.47-4.16) stroke-attributable DALYs. The crude number of incident strokes, prevalent strokes, mortality, and DALYs increased from 1990 to 2019 but age-standardized stroke burden measures declined or remained flat (Figure 1). Trends in stroke incidence, prevalence, mortality, and DALYs varied by age group and geographic location, with stroke incidence decreasing in older adults nationwide and increasing in younger adults (15-49 years) in the South and Midwest US (Figure 2).Conclusions:While age-standardized measures of stroke burden are decreasing, there is a large and increasing number of people affected by stroke in the US, especially among younger populations in the South and Midwest.Public health efforts to reduce stroke burden across the lifespan should incorporate location-specific stroke trends.

Stroke, Volume 53, Issue Suppl_1, Page ATMP97-ATMP97, February 1, 2022. Background:The global burden of diseases (GBD) of neurological disorders is increasing worldwide. The purpose of this study is to determine the burden of neurological disorders, including incidence, prevalence, death, disability-adjusted life-years (DALY), years lived with disability, and years of life lost between 1990 and 2019 in Asia regions.Methods:The GBD study is updated every year, and the most recent version provides the burden of diseases according to age, gender, and region from 1990 to 2019. Our study included 13 neurological diseases including stroke, Alzheimer’s disease and other dementias, Parkinson’s disease, brain and central nervous system cancer, idiopathic epilepsy, motor neuron disease, multiple sclerosis, migraine, tension-type headache, meningitis, encephalitis, tetanus, other neurological disorders. All rates were described as age-standardized using the GBD standard. Data were described using 95% uncertainty intervals (UIs) and changes from 1990 to 2019 as percent (95% UIs) provided by the GBD website.Results:In 2019, DALYs of neurological diseases were 64.4 million in South-East Asia (95% UI 45.2-94.2) and 85.0 million in Western pacific regions (95% UI 63.0-118.5). The three neurological diseases with the highest DALYs in WHO South-East Asia and WHO Western pacific regions in 2019 were stroke, migraine, Alzheimer’s disease and other dementias. DALYs of stroke and Alzheimer’s disease and other dementia, Parkinson’s disease, brain and central nervous system cancer, multiple sclerosis, migraine, and tension type headache increased in both regions in 2019 compared to 1990. Infectious diseases such as tetanus, meningitis, encephalitis decreased in both regions. The age-standardized rate of stroke incidence (-10%, 157 to 141 in South-East Asia, -12%, 211 to 186 in Western Pacific) and mortality (-30%, 135 to 95 in South-East Asia, -42%, 180 to 104 in Western Pacific) decreased markedly in both regions.Conclusion:This study demonstrated the burden of neurological diseases in Asia. To reduce the burden of neurological disease, a strategy suited to the reality of each country will be needed, and this study can serve as the cornerstone of the strategy.

Stroke, Volume 53, Issue Suppl_1, Page AWMP104-AWMP104, February 1, 2022. Introduction:High burden of Metabolic Syndrome (MS) results in incident stroke and poor outcomes. We report contemporary national estimates of stroke prevalence and quantify MS burden and its socio-demographic associates among stroke individuals.Methods:We analyzed 2019 Behavioral Risk Factor Surveillance System data; a nationally representative survey of health-related conditions and behaviors among community dwelling adults. We identified individuals with self-reported stroke and flagged 4 MS indicators (diabetes, hypertension, BMI ≥ 25 kg/m2, hypercholesterolemia). Individuals with ≥ 2 features were categorized as High MS (HMS). We compared socio-demographic characteristics (age, sex, race, education, income, marital and employment status, stroke belt residence) and healthcare utilization (insurance status and frequency of healthcare visits) among HMS and no-HMS groups. We fit survey design logistic regression models with appropriate sampling weights and report national estimates of stroke prevalence and HMS associates.Results:In 2019, there were 8,570,876 adults (≥ 18 years) with stroke in the US; translating into a nationwide prevalence of 3.4% (7.9% among ≥ 65 years). Overall, 94.4% had at least one MS feature; 77.4% had HMS. Advanced age, male sex, non-Hispanic Black (NHB) race and residence in stroke belt region were associated with HMS. Participants with high income (≥ $75,000) and health insurance coverage were less likely to have HMS. In the fully adjusted model, advanced age; Asian American / Pacific Islander race and Hispanic ethnicity (vs. Non-Hispanic White) and residence in the US stroke belt had higher likelihood of HMS (Figure). Healthcare utilization patterns and sex were not significantly associated with HMS. Updated 2020 BRFSS data will be presented.Conclusion:Racial and regional disparities exist in HMS burden among stroke individuals. Targeted MS prevention and management measures are needed for high-risk populations.

Stroke, Volume 53, Issue Suppl_1, Page AWP224-AWP224, February 1, 2022. Background:Stroke and myocardial infarction (MI) prevalence varies by race/ethnicity, as do the risk factors.Methods:We included biyearly data from the 2011-2019 Behavioral Risk Factor Surveillance System (BRFSS) surveys of adults (age ≥18) in the United States. We describe survey-weighted prevalence of self-reported stroke and MI by race and ethnicity. We also describe the prevalence of modifiable vascular risk factors in patients with stroke and MI.Results:The weighted number of U.S. participants represented in BRFSS surveys increased from 237,404,549 in 2011 to 251,703,709 in 2019. Stroke prevalence increased from 2.9% in 2011 to 3.4% in 2019 (